Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Nut Supplementation in Inflammatory Bowel Disease: A Proof-of-Concept Study of Gut Microbiome and Metabolome Effects

A legfontosabb adatok

Ki végzi
Sheba Medical Center
Hol
Izrael1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Résztvevők
60 fő vett részt
Kezdés
2025. febr. 27.
Befejezés
2025. szept. 25.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Mixed Nut Blend
A regiszteradat frissítve
2026. november 17.

Ki vehet részt

Életkor
10 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 6 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with Crohn's disease or ulcerative colitis in clinical remission, as determined by the treating physician
  • Non-IBD volunteers (controls)
  • Willingness and ability to provide written informed consent (and parental/guardian consent for minors)

Ki nem vehet részt

  • Active Crohn's disease or ulcerative colitis
  • Known nut allergy
  • Systemic antibiotic use within 4 weeks preceding enrollment

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

People with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, often continue to experience disruptions in the gut microbiome and metabolism even when their disease is in clinical remission on biologic therapy. These persistent gut-level changes may contribute to disease flares over time.

A teljes eredeti leírásKevesebb

Nuts are nutrient-dense foods rich in unsaturated fats, fiber, minerals, and polyphenols, and have been shown to support gut health in general and cardiometabolic populations. However, their specific effects on the gut microbiome and metabolome in people with IBD in remission have not been examined.

This proof-of-concept study investigated whether short-term, daily consumption of a standardized mixed nut blend (almonds, walnuts, and pecans) shifts the gut microbiome and metabolic signals of people with IBD toward a healthier, control-like profile.

Sixty participants: 21 healthy controls, 19 participants with Crohn's disease in remission, and 20 participants with ulcerative colitis in remission, underwent a 3-day nut-avoidance washout, followed by 10 days of consuming 30 g/day of a mixed nut blend. Fecal samples were collected on days -3, 0, 5, and 10 and analyzed for microbiome composition (16S rRNA sequencing) and metabolite profiles (untargeted LC-MS metabolomics). Participants also completed a food frequency questionnaire and a daily adherence survey.

The study aimed to characterize how a defined, single food item influences gut health signals in IBD remission, providing a foundation for larger, longer-term dietary interventions.

A vizsgálat csoportja

  • Mixed Nut SupplementationA vizsgált kezelés

    All participants received a defined mixed nut blend consisting of equal weights of raw almonds, walnuts, and pecans (10 g of each per daily portion, 30 g total) for 10 consecutive days, following a 3-day nut-avoidance washout period. Portions were pre-weighed, homogenized, sealed in dedicated single-use bags labeled with the intervention day, and distributed to each participant in a coded box of 10 bags.

    Kezelés: Mixed Nut Blend

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Simple Nut Supplementation Induces Positive Gut Metabolic Signals in Patients With Inflammatory Bowel Disease
A regiszteradat frissítve
2026. november 17.